MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/10507256251372191

Медицинская библиотека · Thyroid : official journal of the American Thyroid Association · 2025

Immunotherapy in Initial Treatment of Anaplastic Thyroid Cancer: Evaluation of Overall Survival in a National Cancer Database Study.

Kini Shikha, Yildiz Vedat, Mitchell Darrion, Gogineni Emile, Grecula John, Konieczkowski David, Zhu Simeng, Ma Sung Jun, Bhateja Priyanka, Old Matthew, Seim Nolan, Blakaj Dukagjin M, Patel Dipen, Sukrithan Vineeth, Konda Bhavana, Baliga Sujith

СтатьяПеревод пока не подготовлен

Аннотация

Background

Anaplastic thyroid cancer (ATC) is an aggressive malignancy with a median survival of six months. While immunotherapy (IT) has improved outcomes in other solid tumors, its role in ATC remains unclear. This study evaluated whether receipt of IT was associated with improved overall survival (OS) in the initial treatment of patients with newly diagnosed ATC.

Methods

We performed a retrospective study of patients with metastatic and nonmetastatic ATC from the National Cancer Database (2008-2020) treated with surgery, radiation, chemotherapy, or a combination. Patient outcomes were stratified between those who received IT at any point in their treatment compared with those who did not. The primary outcome was OS, compared between cohorts receiving IT and those who did not. Survival analyses were performed using Kaplan-Meier estimates, long-rank tests, and multivariable models.

Results

Among 3318 patients with ATC, 87 (2.6%) received IT. Rates of surgical resection (46%) and radiation therapy (64% vs. 57%, p = 0.133) were similar across groups. IT recipients were younger (mean = 66.7 vs. 70.2 years, p = 0.005), more often diagnosed in recent years (2017-2019 vs. 2008-2016, p = 0.0001), and more frequently received chemotherapy (65.5% vs. 46.3%, p = 0.0007). Charlson Comorbidity Index scores were similar (p = 0.551). Median OS was 9.1 months (confidence interval [CI] 7.06-14.9) for those receiving IT versus 3.78 months (CI: 3.52-4.01) for those who did not (p < 0.005). Five-year OS was 18% (CI: 5-36%) with IT versus 9% (CI: 8-10%) without (p < 0.0001). Among 23 patients who received trimodality therapy (surgery, IT, and radiation), 5-year OS was 35% (CI: 16-55%) versus 9% in patients who did not.

Conclusions

IT was associated with prolonged survival in patients with ATC, although confounding factors, such as the retrospective design of the study, lack of detailed IT drug details, and sequencing of therapy, preclude definitive conclusions on its efficacy. The efficacy of IT for ATC as a stand-alone treatment is uncertain. Further studies could indicate which combination of therapies best increases OS in patients with ATC.

Для цитирования: Kini Shikha, Yildiz Vedat, Mitchell Darrion, Gogineni Emile, Grecula John, Konieczkowski David, Zhu Simeng, Ma Sung Jun, Bhateja Priyanka, Old Matthew, Seim Nolan, Blakaj Dukagjin M, Patel Dipen, Sukrithan Vineeth, Konda Bhavana, Baliga Sujith. Immunotherapy in Initial Treatment of Anaplastic Thyroid Cancer: Evaluation of Overall Survival in a National Cancer Database Study.. Thyroid : official journal of the American Thyroid Association. 2025. DOI: 10.1177/10507256251372191.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.